Plain English Summary
Background and study aims
A DHEP medicated plaster contains 180 mg of a diclofenac salt, named diclofenac epolamine or DHEP, and it allows a continuous release of the drug from the plaster during the application period. This plaster has been marketed by many years in Europe and USA for the local treatment of pain and inflammation of traumatic and rheumatic origin. Our goal was to demonstrate how well the DHEP plaster works for the treatment of minor soft tissue injuries in the Chinese population.
Who can participate?
Adult male and female patients (18-65 years) with a minor soft tissue injury, such as ankle or knee joint sprain, muscle strain or contusion, which has occurred within the last 72 hours.
What does the study involve?
Participants were randomly allocated to one of two groups. One group of patients applied two DHEP plasters per day, each for 12 hours, for 7 days. The other group applied a placebo (dummy) plaster instead. During the study the severity of pain was measured using an established scale. The safety was also assessed by blood and urinalysis at the beginning and at the end of the study.
What are the possible benefits and risks of participating?
The participants who received the DHEP plaster can expect an improvement of their pain symptoms. The most common side effects seen with DHEP plasters are skin reactions (including itching, inflamed skin, burning) at the site of treatment.
Where is the study run from?
From 10 medical centres in China, with Peking University First Hospital in Beijing as lead centre.
When is the study starting and how long is it expected to run for?
The study started in April 2010 and ended in November 2010 when the required number of 384 patients (192 for each group) was recruited and treated.
Who is funding the study?
IBSA Institut Biochimique (Switzerland)
Who is the main contact?
Dr Chunde Li
lichunde@medmail.com.cn
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
09RC-Fp14
Study information
Scientific title
A multicentre, randomised, double-blind, placebo-controlled confirmatory clinical trial of the efficacy and safety of diclofenac epolamine medicated plaster in the treatment of minor soft tissue injuries
Acronym
Study hypothesis
To evaluate the efficacy and safety of DHEP medicated plaster for the treatment of minor soft tissue injury when compared to placebo.
Ethics approval
Ethics Committee of Peking University First Hospital (China), 17 March 2010, Approval number: 2009L00819
Study design
Multicenter double-blind placebo-controlled randomized confirmatory phase III study
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Minor soft tissue injuries, such as ankle or knee joint sprains, muscle strains or contusions
Intervention
Patients were randomised to receive either
1. DHEP medicated plaster (Flector®, IBSA Institut Biochimique SA): twice daily (morning and evening, every 12 hours) for 7 days
2. Placebo plaster: twice daily (morning and evening, every 12 hours) for 7 days
Intervention type
Drug
Phase
Phase III
Drug names
Diclofenac epolamine
Primary outcome measure
Reduction in pain on movement (VAS score) at the end of treatment (Day 7), as com-pared to pre-treatment scores
Secondary outcome measures
1. Pain on movement day-by-day evaluation (VAS score)
2. Summed pain intensity difference (SPID)
3. Rescue medication consumption (paracetamol)
4. Overall treatment efficacy as judged by patient and Investigator
5. Compliance to treatment
6. Overall treatment tolerability as judged by patient and Investigator
7. Adverse events
8. Pre-/post-treatment changes in haematology, blood chemistry, urinalysis or ECG tests
Overall trial start date
01/04/2010
Overall trial end date
30/11/2010
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Outpatients and emergency patients of both gender
2. Aged between 18 and 65 years
3. With a minor soft tissue injury occurred within the past 72 hours
4. With pain on movement greater than or equal to 50 mm on VAS
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
384
Participant exclusion criteria
1. Severe injuries requiring orthopaedic, surgical or physiotherapeutic treatment
2. Open skin lesion or any dermatological condition at treated site
3. Administration of any topical medication within the past 24 hours
4. Administration of OTC analgesic or NSAIDs within the past 36-48 hours
5. Administration of long-acting NSAIDs within the past 72 hours
6. Administration of narcotic analgesics within the past 7 days
7. Administration of systemic anti-inflammatory steroidal drugs within the past 60 days
Recruitment start date
01/04/2010
Recruitment end date
30/11/2010
Locations
Countries of recruitment
China
Trial participating centre
Department of Orthopaedics
Beijing
100034
China
Sponsor information
Organisation
Institut Biochimique SA (IBSA) (Switzerland)
Sponsor details
Via del Piano
Pambio-Noranco
6915
Switzerland
stefano.rovati@ibsa.ch
Sponsor type
Industry
Website
Funders
Funder type
Industry
Funder name
IBSA Institut Biochimique SA (Switzerland)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list